lutetium has been researched along with Local Neoplasm Recurrence in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mumtaz, M; Shahid, A; Sheikh, N; Younis, MN | 1 |
| Jacobs, N; More, S; Naiker, T; Oompie, F; Prasad, V | 1 |
| Akbarian, R; Fattahi, K; Ghodsirad, MA; Javanmard, B; Kaghazchi, F; Pirayesh, E; Tavakoli, M | 1 |
| Ahmadzadehfar, H; Alamdar, R; Attenberger, U; Conrad, R; Essler, M; Marinova, M; Mücke, M | 1 |
| Bartolomei, M; Iannicelli, E; Magi, L; Panareo, S; Panzuto, F; Prosperi, D; Rinzivillo, M | 1 |
| Acar, O; Demirkol, MO; Esen, T; Falay, O; Kiremit, MC; Ucar, B | 1 |
| Antonarakis, ES; Denmeade, SR; Eisenberger, MA; Eshleman, JR; Isaacsson Velho, P; Luo, J; Paller, CJ; Piana, D; Pomper, MG; Riel, S; Rowe, SP | 1 |
| Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G | 1 |
| Aarts, F; Bleichrodt, RP; Boerman, OC; de Jong, GM; Hendriks, T; Heskamp, S | 1 |
| Bleichrodt, RP; Boerman, OC; de Jong, GM; Eek, A; Hendriks, T; Nagtegaal, ID; Oyen, WJ | 1 |
1 trial(s) available for lutetium and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2020 |
9 other study(ies) available for lutetium and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Tc-99m PSMA and Lu-177 PSMA Theranostic Pair in a Patient of Metastatic Castration Resistant Prostate Cancer.
Topics: Humans; Lutetium; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2021 |
Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma.
Topics: Adult; Dipeptides; Glioblastoma; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Recurrence, Local; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
Topics: Aged; Aged, 80 and over; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2020 |
Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response.
Topics: Humans; Lutetium; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide; Retreatment | 2021 |
Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177.
Topics: Administration, Intravenous; Antigens, Surface; Brachytherapy; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Salvage Therapy; Theranostic Nanomedicine; Treatment Outcome | 2018 |
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Bridged-Ring Compounds; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; RNA, Messenger; Taxoids; Treatment Outcome | 2019 |
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome | 2016 |
Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model.
Topics: Animals; Antibodies, Monoclonal; Body Weight; Cell Line, Tumor; Colonic Neoplasms; Lutetium; Male; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Rats; Tumor Burden | 2009 |
Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Colorectal Neoplasms; Hepatectomy; Indium Radioisotopes; Liver Neoplasms; Lutetium; Male; Neoplasm Recurrence, Local; Radioimmunotherapy; Radioisotopes; Radiotherapy, Adjuvant; Rats; Rats, Inbred Strains; Survival Rate | 2011 |